Inhibrx Biosciences (INBX) Operating Leases (2023 - 2025)
Historic Operating Leases for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $7.0 million.
- Inhibrx Biosciences' Operating Leases rose 28081.74% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 28081.74%. This contributed to the annual value of $8.0 million for FY2024, which is 15364.01% up from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Operating Leases is $7.0 million, which was up 28081.74% from $7.5 million recorded in Q2 2025.
- Inhibrx Biosciences' Operating Leases' 5-year high stood at $8.0 million during Q4 2024, with a 5-year trough of $1.8 million in Q3 2024.
- Over the past 3 years, Inhibrx Biosciences' median Operating Leases value was $7.0 million (recorded in 2025), while the average stood at $5.4 million.
- As far as peak fluctuations go, Inhibrx Biosciences' Operating Leases soared by 15364.01% in 2024, and later skyrocketed by 28081.74% in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Operating Leases stood at $3.2 million in 2023, then soared by 153.64% to $8.0 million in 2024, then fell by 13.17% to $7.0 million in 2025.
- Its Operating Leases was $7.0 million in Q3 2025, compared to $7.5 million in Q2 2025 and $7.9 million in Q1 2025.